Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.51), $0.10 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $25.51 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.